Today: 14 May 2026

Skeena Resources stock rises today as gold rebounds and Eskay Creek decision watch intensifies

Skeena Resources stock rises today as gold rebounds and Eskay Creek decision watch intensifies

Skeena Resources climbed 3.4% to $24.57 in midday New York trading Tuesday, tracking gains in gold and silver after Monday’s sharp drop. About 565,000 shares traded, below average volume. Investors are watching for Federal Reserve minutes and a January consent decision on the Eskay Creek project, after the Tahltan Nation backed an Impact Benefit Agreement this month.
30 December 2025
··
Newmont stock rises as gold rebounds; Raymond James lifts $111 target

Newmont stock rises as gold rebounds; Raymond James lifts $111 target

Newmont Corp shares climbed 2.2% to $102.00 in midday trading Tuesday, rebounding after a 5.6% drop Monday as gold prices steadied. Spot gold rose 0.9% to $4,369.59 an ounce, recovering from its sharpest daily loss since October. Raymond James raised its price target on Newmont to $111. CEO Tom Palmer will step down Dec. 31, with Natascha Viljoen set to take over Jan. 1.
30 December 2025
··
Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics stock steady midday after $3 million insider sale filing — what’s next for EWTX

Edgewise Therapeutics shares rose 0.2% to $24.68 after a Form 144 filing showed officer Robert Michael Carruthers sold 116,665 shares for about $3.04 million on Dec. 26. The stock traded between $24.40 and $24.92 midday. The sale followed a Dec. 24 update on the company’s Phase 2 trial of EDG-7500 in hypertrophic cardiomyopathy. Biotech stocks broadly traded lower.
30 December 2025
·
AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

AST SpaceMobile stock jumps 6% today as launch cadence and insider buy lift sentiment

AST SpaceMobile shares climbed 6.5% to $76.09 in midday trading Tuesday after the company said its BlueBird 6 satellite is expected to begin operations in the coming weeks. COO Shanti B. Gupta outlined plans for faster launches into early 2026. Director Keith Larson bought 625 shares last week under a pre-arranged plan, according to a U.S. regulatory filing.
30 December 2025
··
Why Triple Flag Precious Metals (TFPM) stock is up today: gold rebounds, Fed minutes ahead

Why Triple Flag Precious Metals (TFPM) stock is up today: gold rebounds, Fed minutes ahead

Triple Flag Precious Metals shares rose 1.9% to $33.76 by late morning Tuesday, tracking a rebound in spot gold, which gained 0.9% to $4,369.59 an ounce. Other royalty and streaming firms, including Franco-Nevada and Wheaton Precious Metals, also edged higher as investors watched for signals from the Federal Reserve on interest rates amid year-end volatility.
30 December 2025
···
NovaGold (NG) stock steadies as gold rebounds after CME margin hike; Fed minutes in focus

NovaGold (NG) stock steadies as gold rebounds after CME margin hike; Fed minutes in focus

NovaGold shares rose 0.5% to $9.54 by midday Tuesday after a 6.8% drop in the previous session. Spot gold rebounded 0.9% to $4,369.59 an ounce, recovering from its steepest loss since October. Traders awaited the Federal Reserve’s meeting minutes and monitored developments at the Donlin Gold project, where NovaGold’s stake recently increased to 60%.
30 December 2025
·····
PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

PSLV stock pops as silver rebounds from record-high whipsaw; Fed minutes in focus

Sprott Physical Silver Trust jumped 4.4% to $25.33 Tuesday, tracking a 4.6% rebound in spot silver after Monday’s steep drop triggered by higher futures margin requirements. Volume in PSLV neared 9.8 million shares. The iShares Silver Trust also climbed 4.7%. Investors awaited Federal Reserve minutes later Tuesday for signals on 2026 interest rates.
30 December 2025
····
PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect

PepsiCo (PEP) stock edges lower today as Fed minutes loom and leadership shuffle takes effect

PepsiCo shares slipped 0.1% to $144.10 in midday trading Tuesday, mirroring a slight dip in the consumer staples sector. The company named Steven Williams as global chief commercial officer and Ram Krishnan as CEO of North America, both effective Dec. 28. PepsiCo expects 2026 organic revenue growth of 2% to 4% and core EPS up 4% to 6%. Elliott Management reportedly holds a $4 billion stake and is nearing a settlement with PepsiCo.
30 December 2025
··
Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus stock halted today as Genmab buyout closes: what happens to MRUS shares and the $97 cash payout

Merus N.V. shares were halted Tuesday after Nasdaq confirmed Genmab’s $97-a-share cash acquisition closed, with trading set for suspension Dec. 31. Holders will receive $97 per share minus a $10.67 Dutch dividend withholding tax, leaving about $86.33 before any refund. Merus requested delisting, and two directors resigned as the merger became effective. Genmab’s U.S. shares fell about 2% in late-morning trading.
30 December 2025
··
Lumentum stock rebounds today after Monday slide as year-end trading stays thin

Lumentum stock rebounds today after Monday slide as year-end trading stays thin

Lumentum shares rose 1.3% to $377.59 in midday trading Tuesday, recovering part of Monday’s 4.65% slide. Trading volume was about 800,000 shares, with the stock moving between $370 and $380.32. Optical-component peers were mixed, as Applied Optoelectronics gained and IPG Photonics slipped. Investors cited thin holiday liquidity and awaited U.S. economic data for direction.
30 December 2025
·····
1 … 958 959 960 961 962 … 1,934

Stock Market Today

  • Nurix Therapeutics Stock: Is Its Premium 23.3x Price-to-Sales Multiple Justified?
    May 14, 2026, 9:02 AM EDT. Nurix Therapeutics (NRIX) shares rose 1.38% to $16.18 amid mixed recent performance, down 10% year to date but up nearly 69% over one year. The stock trades at a high price-to-sales (P/S) multiple of 23.3x, well above the US biotech average of 9.7x. This premium reflects strong analyst revenue growth forecasts of 42.2% annually, outpacing the broader market. However, Nurix remains loss-making with $295 million in ongoing losses and a $1.65 billion market cap, making it vulnerable to clinical setbacks. Investors should weigh the high growth potential against risks in this early-stage biotech before assuming the premium valuation is sustainable.

Latest articles

Apple Backs Google in EU AI Fight as iPhone Rules Loom

Apple Backs Google in EU AI Fight as iPhone Rules Loom

14 May 2026
Apple warned the European Commission that proposed EU rules forcing Google’s Android to open core features to rival AI assistants could endanger privacy, security, and device performance. The Commission’s feedback period closed Wednesday, with a final decision expected by July 27. Apple argued the measures could set a precedent for its own platforms. Google also opposes the plan, calling it an “unwarranted intervention.”
Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

Precigen Stock Jumps as Papzimeos Sales Change the Story for PGEN Investors

14 May 2026
Precigen shares jumped 14.1% in early trading after first-quarter revenue reached $23.3 million, beating estimates, and net loss narrowed to $7.9 million from $54.2 million a year earlier. Papzimeos, its new RRP therapy, generated $21.6 million in net product revenue. The company ended March with $56.7 million in cash and expects current funds and Papzimeos sales to last through 2026.
POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

POET Stock Jumps After $50 Million Lumilens AI Optics Order — The Bigger Test Comes Later

14 May 2026
POET Technologies signed a supply and joint-development agreement with Lumilens, including a $50 million initial order for optical engines used in AI data-center networks. The companies said cumulative purchases could exceed $500 million over five years. POET shares rose 16% after the news. First engineering samples are expected in late 2026, with production targeted for 2027.
Go toTop